Medtronic plc

Medtronic plc is an American-Irish medical device company and a global leader in healthcare technology, dedicated to developing and manufacturing technologies and therapies. The company's mission, established by its founder, is "to contribute to human welfare by the application of biomedical engineering in the research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life." While its legal and executive headquarters are located in Ireland, its operational headquarters are in Minneapolis, Minnesota, U.S..

Medtronic offers a broad spectrum of medical devices and therapies designed to treat over 70 health conditions. Its key product areas span four main portfolios: Cardiovascular (including pacemakers, cardiac ablation, and structural heart solutions), Neuroscience (such as spinal implants, neuromodulation, and deep brain stimulation for conditions like Parkinson's, epilepsy, and OCD), Medical Surgical (encompassing surgical tools, endoscopy, acute care monitoring, and robotic-assisted surgery), and Diabetes management (featuring insulin pumps and continuous glucose monitoring systems). The company operates in over 150 countries, serving a diverse customer base that includes hospitals, clinics, healthcare providers, and patients worldwide..

Under the leadership of Chairman and CEO Geoff Martha, Medtronic recently reported its highest annual revenue growth in a decade for fiscal year 2026, demonstrating strong market positioning as one of the world's largest medical device companies by revenue. Recent strategic activities include investments in intracardiac echocardiography (ICE) catheter technologies to bolster its cardiac ablation portfolio and the acquisition of Scientia Vascular. The company also submitted 510(k) filings to expand its Hugo™ robotic-assisted surgery system and announced plans to acquire SPR Therapeutics, Inc. to enhance its neuromodulation offerings. Furthermore, Medtronic received U.S. FDA approval for its BrainSense Adaptive deep brain stimulation (aDBS) system for Parkinson's disease, marking a significant advancement in personalized neurological care..